Brain (and spinal cord) tumours, Children's cancers
Results
Phase 3
This trial compared standard radiotherapy with hyperfractionated radiotherapy (HFRT) for children and young people with medulloblastoma. This trial was supported by Cancer Research UK.
This trial was for children from 4 years old and young people up to and including the age of 21. We use the term 'you' in this summary, but of course if you are a parent, we are referring to your child.
Medulloblastoma is a type of brain tumour called a primitive neuroectodermal tumour (PNET). It grows in the hind brain (the cerebellum). It is the most common malignant brain tumour in children.
In some children, the medulloblastoma does not spread to the rest of the brain or spinal cord. Doctors call this ‘standard risk’. Treatment for standard risk medulloblastoma includes surgery to remove as much of the cancer as possible. But there may be cancer cells left behind. So children have radiotherapy and chemotherapy after surgery.
This trial tried to find the best way of giving radiotherapy to children with medulloblastoma. It compared the standard treatment of daily radiotherapy with hyperfractionated radiotherapy (HFRT). Children had HFRT twice a day instead of once. They had smaller doses, but the dose of radiotherapy overall was bigger. The researchers thought HFRT may kill more cancer cells than standard radiotherapy. The aim of the trial was to find out which method
Was better at stopping the cancer from coming back
Had the fewest side effects
Recruitment start: 1 December 2003
Recruitment end: 31 December 2006
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Barry Pizer
Cancer Research UK
Cancer Research UK Children's Cancer Trials Team
University of Birmingham
National Institute for Health Research Cancer Research Network (NCRN)
This is Cancer Research UK trial number CRUK/03/012.
Last reviewed: 12 November 2012
CRUK internal database number: 358